Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals

Jonathan N. Hofmann, Brenda M. Birmann, Lauren R. Teras, Ruth M. Pfeiffer, Ye Wang, Demetrius Albanes, Dalsu Baris, Graham A. Colditz, Anneclaire J. De Roos, Graham G. Giles, Howard D. Hosgood, Qing Lan, Ola Landgren, Linda M. Liao, Nathaniel Rothman, Stephanie J. Weinstein, Michael N. Pollak, Marian L. Neuhouser, Mark P. Purdue

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.

Original languageEnglish (US)
Pages (from-to)1935-1941
Number of pages7
JournalCancer Research
Volume76
Issue number7
DOIs
StatePublished - Apr 1 2016

Fingerprint

Adiponectin
Multiple Myeloma
Confidence Intervals
Weights and Measures
Body Mass Index
Obesity
Enzyme-Linked Immunosorbent Assay
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hofmann, J. N., Birmann, B. M., Teras, L. R., Pfeiffer, R. M., Wang, Y., Albanes, D., ... Purdue, M. P. (2016). Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. Cancer Research, 76(7), 1935-1941. https://doi.org/10.1158/0008-5472.CAN-15-2406

Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. / Hofmann, Jonathan N.; Birmann, Brenda M.; Teras, Lauren R.; Pfeiffer, Ruth M.; Wang, Ye; Albanes, Demetrius; Baris, Dalsu; Colditz, Graham A.; De Roos, Anneclaire J.; Giles, Graham G.; Hosgood, Howard D.; Lan, Qing; Landgren, Ola; Liao, Linda M.; Rothman, Nathaniel; Weinstein, Stephanie J.; Pollak, Michael N.; Neuhouser, Marian L.; Purdue, Mark P.

In: Cancer Research, Vol. 76, No. 7, 01.04.2016, p. 1935-1941.

Research output: Contribution to journalArticle

Hofmann, JN, Birmann, BM, Teras, LR, Pfeiffer, RM, Wang, Y, Albanes, D, Baris, D, Colditz, GA, De Roos, AJ, Giles, GG, Hosgood, HD, Lan, Q, Landgren, O, Liao, LM, Rothman, N, Weinstein, SJ, Pollak, MN, Neuhouser, ML & Purdue, MP 2016, 'Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals', Cancer Research, vol. 76, no. 7, pp. 1935-1941. https://doi.org/10.1158/0008-5472.CAN-15-2406
Hofmann, Jonathan N. ; Birmann, Brenda M. ; Teras, Lauren R. ; Pfeiffer, Ruth M. ; Wang, Ye ; Albanes, Demetrius ; Baris, Dalsu ; Colditz, Graham A. ; De Roos, Anneclaire J. ; Giles, Graham G. ; Hosgood, Howard D. ; Lan, Qing ; Landgren, Ola ; Liao, Linda M. ; Rothman, Nathaniel ; Weinstein, Stephanie J. ; Pollak, Michael N. ; Neuhouser, Marian L. ; Purdue, Mark P. / Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. In: Cancer Research. 2016 ; Vol. 76, No. 7. pp. 1935-1941.
@article{74c0b9e593bd42cf8f9985540814b59e,
title = "Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals",
abstract = "The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95{\%} confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95{\%} CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95{\%} CI, 0.26-0.65) or obese (OR, 0.41; 95{\%} CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95{\%} CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.",
author = "Hofmann, {Jonathan N.} and Birmann, {Brenda M.} and Teras, {Lauren R.} and Pfeiffer, {Ruth M.} and Ye Wang and Demetrius Albanes and Dalsu Baris and Colditz, {Graham A.} and {De Roos}, {Anneclaire J.} and Giles, {Graham G.} and Hosgood, {Howard D.} and Qing Lan and Ola Landgren and Liao, {Linda M.} and Nathaniel Rothman and Weinstein, {Stephanie J.} and Pollak, {Michael N.} and Neuhouser, {Marian L.} and Purdue, {Mark P.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-15-2406",
language = "English (US)",
volume = "76",
pages = "1935--1941",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals

AU - Hofmann, Jonathan N.

AU - Birmann, Brenda M.

AU - Teras, Lauren R.

AU - Pfeiffer, Ruth M.

AU - Wang, Ye

AU - Albanes, Demetrius

AU - Baris, Dalsu

AU - Colditz, Graham A.

AU - De Roos, Anneclaire J.

AU - Giles, Graham G.

AU - Hosgood, Howard D.

AU - Lan, Qing

AU - Landgren, Ola

AU - Liao, Linda M.

AU - Rothman, Nathaniel

AU - Weinstein, Stephanie J.

AU - Pollak, Michael N.

AU - Neuhouser, Marian L.

AU - Purdue, Mark P.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.

AB - The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.

UR - http://www.scopus.com/inward/record.url?scp=84963768563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963768563&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2406

DO - 10.1158/0008-5472.CAN-15-2406

M3 - Article

C2 - 26921332

AN - SCOPUS:84963768563

VL - 76

SP - 1935

EP - 1941

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -